NEUP
Neuphoria Therapeutics Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Neuphoria Therapeutics (NEUP) Stock: Buy, Sell, or Hold?
$2.55
-0.03 (-1.16%)
▼
5d:
-8.27%
30d:
-22.96%
90d:
-33.77%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (83%)
Quality Score
42/100
Position
OVERSOLD
30-Day Fair Range
$2.86 – $3.46
Position: OVERSOLD
Forward P/E & Valuation
-1.1x
Next 12M consensus est.
Wall Street Target
$7.00
+174.5% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$2.49 / $3.14
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: NEUP shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When NEUP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: NEUP is currently trading at $2.55, which is considered oversold relative to its 30-day fair value range of $2.86 to $3.46.
Technical Outlook: Technically, NEUP is in a downtrend. The price is currently testing key support at $2.49. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.00 (+174.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NEUP is in a downtrend. The price is currently testing key support at $2.49. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.00 (+174.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.86 -
$3.46
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
Trading Range & Key Levels
30-Day Trading Range
$2.86 -
$3.46
Current vs Trading Range
OVERSOLD
Support Level
$2.49
Resistance Level
$3.14
Current Trend
Downtrend
Technical data as of
Nov 13, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 174.5% below Wall St target ($7.00)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-1.05
Wall Street Target
$7.00
(+174.5%)
Share NEUP Analysis
Share this live NEUP analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.
Last updated: November 13, 2026 5:44 PM ET
Data refreshes hourly during market hours. Next update: 6:44 PM
Data refreshes hourly during market hours. Next update: 6:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NEUP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 33 SELL |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 39 SELL |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
18 analysts |
$139 | 35 SELL |
|
ARDX
Ardelyx Inc |
STRONG BUY
11 analysts |
$13 | 69 BUY |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive NEUP Research Pages
